Product Description
Mechanisms of Action: Cell Wall Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intramuscular, Intravenous, Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Brazil | Chile | China | Colombia | Greece | India | Malaysia | Pakistan | Peru | Philippines | Portugal | Romania | Russia | Saudi Arabia | South Africa | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: TASK Applied Science
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: South Africa
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Tuberculosis|Tuberculosis, Pulmonary
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06748937 |
ENABLE | P2 |
Recruiting |
Tuberculosis |
2026-03-30 |
2025-03-08 |
||
NCT05473195 |
BETO | P2 |
Completed |
Tuberculosis, Pulmonary |
2024-04-16 |
2025-08-22 |
Patient Enrollment|Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|
